The identification of gene fusions from RNA sequencing data is a routine task in cancer
research and precision oncology. However, despite the availability of many computational …

The clinical relevance of comprehensive molecular analysis in rare cancers is not
established. We analyzed the molecular profiles and clinical outcomes of 1,310 patients …

Background Although the incidence of Cancer of Unknown Primary (CUP) is estimated to be
1–2% of all cancers worldwide, no international standards for diagnostic workup are yet …

The benefit of molecularly-informed therapies in cancer of unknown primary (CUP) is
unclear. Here, we use comprehensive molecular characterization by whole genome/exome …

In the last decades, the development of high‐throughput molecular assays has
revolutionised cancer diagnostics, paving the way for the concept of personalised cancer …

Next‐generation sequencing has become a cornerstone of therapy guidance in cancer
precision medicine and an indispensable research tool in translational oncology. Its rapidly …

Background Germline variant evaluation in precision oncology opens new paths toward the
identification of patients with genetic tumor risk syndromes and the exploration of therapeutic …

Abstract Analysis of selected cancer genes has become an important tool in precision
oncology but cannot fully capture the molecular features and, most importantly …

Whole exome sequencing (WES) is used to identify mutations in a patient's tumor DNA that
are predictive of tumor behavior, including the likelihood of response or resistance to cancer …

Over the past decade, Next-Generation Sequencing (NGS) has advanced our
understanding, diagnosis, and management of several areas within dermatology. NGS has …